One day after Biogen expands aducanumab trials, a canary in the coal mine, the rival crenezumab, fails in phase III.
Celgene’s Revlimid ranks as biopharma’s most contested blockbuster, with a huge spread in future sales forecasts, while drugs from Bristol-Myers Squibb and Sanofi also…
Two weeks ago BAN2401 was hailed as a possible disease-modifying Alzheimer's drug. Full data at the AAIC meeting to will show whether or not this is was all hype.
Immunocore and Adaptimmune could shortly have a publicly listed rival.